The multiple sclerosis risk sharing scheme monitoring study - Early results and lessons for the future

BMC Neurology

Volumn 9, Issue , 2009, Pages

  Pickin, Mark ^a   Cooper, Cindy L ^a   Chater, Timothy ^a   O'Hagan, Anthony ^b   Abrams, Keith R ^c   Cooper, Nicola J ^c   Boggild, Mike ^d   Palace, Jackie ^e   Ebers, George ^e   Chilcott, James B ^a   Tappenden, Paul ^a   Nicholl, Jon ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; RISK ASSESSMENT; UNITED KINGDOM; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HEALTH SERVICES RESEARCH; MIDDLE AGED; PROSPECTIVE STUDY; RISK MANAGEMENT;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ORGANIZATIONAL CASE STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; PROSPECTIVE STUDIES; RISK SHARING, FINANCIAL;

EID: 60649121546     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-9-1     Document Type: Article

References (13)

1. NICE Technology Appraisal Guidance No.32. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis London 2002
2. Chilcott J McCabe C Tappenden P O'Hagan A Cooper NJ Abrams K Claxton K Miller DH: On behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003, 326(7388):522. 150460 12623909 10.1136/bmj.326.7388.522
3. Department of Health: Cost Effective Provision of Disease Modifying Therapies for people with Multiple Sclerosis. Health Service Circular 2002.
4. Association of British Neurologists: Guidelines for Use of Beta Interferons and Glatiramer Acetate in Multiple Sclerosis 2001
5. Kurtzke JF: Rating neurological impairment in muAtiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983, 33:1444-1452. 6685237
6. Weinshenker BG Rice GP Noseworthy JH Carriere W Baskerville J Ebers GC: The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991, 114(Pt 2):1045-1056. 10.1093/brain/114.2.1045 2043940
7. Filippini G Munari L Incorvaia B Ebers G Polman C D'Amico R Rice G: Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet 2003, 361(9357):545-552. 10.1016/S0140-6736(03)12512-3 12598138
8. Kobelt G Berg J Lindgren P Fredrikson S Jonsson B: Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006, 77(8):C918-926. 10.1136/jnnp.2006.090365
9. Clarke M. Population laboratories and health needs assessment. Int J Epidemiol 1995, 24(Suppl 1): S65-S68. 7558554
10. Sudlow CLM Counsell CE: Problems with the UK government's risk sharing scheme for assessing drugs for sclerosis. BMJ 2003, 326:388-392. 1125245 12586677 10.1136/bmj.326.7385.388
11. Tremlett H Paty D Devonshire V: Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006, 66(2):172-177. 10.1212/01.wnl.0000194259.90286.fe 16434648
12. Río J Nos C Tintoré M Téllez N Galán I Pelayo R Comabella M Montalban X. Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006, 59:344-352. 10.1002/ana.20740 16437558
13. Orton S Herrera BM Yee IM Valdar W Ramagopalan SV Sadovnick AD Ebers GC: for the Canadian Collaborative Study Group Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006, 5:932-36. 10.1016/S1474-4422(06)70581-6 17052660